Voltaren Emulgel gel for external use

Country: Арменија

Језик: Енглески

Извор: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активни састојак:

diclofenac (diclofenac diethylamine)

Доступно од:

GlaxoSmithKline Consumer Healthcare S.A.

АТЦ код:

M02AA15

INN (Међународно име):

diclofenac (diclofenac diethylamine)

Дозирање:

20mg/g

Фармацеутски облик:

gel for external use

Јединице у пакету:

50g laminated tube, 100g laminated tube

Тип рецептора:

OTC

Статус ауторизације:

Registered

Датум одобрења:

2020-09-05

Карактеристике производа

                                GSK Consumer Healthcare S.A.,
Switzerland.
Summary of Product Characteristics
Global Labeling
VOLTAREN EMULGEL
Gel
Diclofenac diethylamine 2.32%
SUMMARY OF PRODUCT CHARACTERISTICS
Document status:
FINAL
Release date:
13 Apr 2020
Number of pages:
8
GSK Consumer Healthcare S.A.,
Switzerland.
Summary of Product Characteristics
TABLE OF CONTENTS
1
NAME OF THE MEDICINAL PRODUCT
.......................................................................
3
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
............................................. 3
3
PHARMACEUTICAL FORM
............................................................................................
3
4
CLINICAL PARTICULARS
..............................................................................................
3
4.1
Pharmacotherapeutic group
.....................................................................................
3
4.2
Posology and method of administration
.................................................................. 3
4.3
Contraindications
.....................................................................................................
4
4.4
Special warnings and precautions for use
................................................................ 4
4.5
Interaction with other medicinal products and other forms of
interaction .............. 5
4.6
Pregnancy and lactation
...........................................................................................
5
4.7
Effects on ability to drive and use machines
........................................................... 5
4.8
Undesirable effects
..................................................................................................
5
4.9
Overdose
..................................................................................................................
6
5 PHARMACOLOGICAL PROPERTIES
..........................................................................
6
5.1 Pharmacodynamic properties
....................................................................................
                                
                                Прочитајте комплетан документ
                                
                            

Документи на другим језицима

Информативни летак Информативни летак Руски 05-09-2020

Обавештења о претрази у вези са овим производом

Погледајте историју докумената